CDK4 and neoplasm: To date, several biomarkers involved in CDK4/6 resistance have been identified, including cell cycle mediators, genes participating in oncogenic kinase pathways [16,17], and genes regulating the tumor microenvironment, which have been shown to clearly influence the antitumor response elicited by CDK4/6 inhibitors [18].